A biregional survey and review of first-line treatment failure and second-line pediatric antiretroviral access and use in Asia and southern Africa

Abstract

Correction The article published in [1], contains incorrect data in Table 1 regarding the nationally recommended paediatric second-line ART regimen after NNRTI failure in India. This has been corrected. The editors and authors regret the inconvenience caused to readers by the error in the original paper. Table 1 First- and second-line antiretroviral therapy regimens in use in TREAT Asia and IeDEA Southern Africa Site Country Nationally recommended paediatric first-line ART regimen* Nationally recommended paediatric second-line ART regimen after NNRTI Most commonly used second-line regimen in current site cohort TREAT Asia National Center for HIV, AIDS, Dermatology, and Sexually Transmitted Infections Cambodia d4T or AZT+3TC+NVP or EFVIf NNRTI exposure:d4T+3TC+LPV/r ABC+ ddI+LPV/r ABC+3TC+LPV/r Beijing Ditan Hospital China d4T or AZT+3TC+NVP or EFVIf NNRTI exposure:AZT+3TC+LPV/r ABC+3TC+AZT+LPV/r ABC+3TC+AZT+LPV/r YRG Centre for AIDS Research and Education India d4T or AZT+3TC+NVP or EFV ABC+ddI+3TC+LPV/r TDF or ddI+3TC or FTC+LPV/r Cipto Mangunkusumo Hospital Indonesia d4T or AZT+3TC+NVP or EFV ddI+3TC+LPV/r ddI+3TC+LPV/r Hospital Kuala Lumpur Malaysia <3yr:AZT+3TC or ddI+NVP≥3yr:AZT+3TC or ddI+EFV 2 new NRTI+LPV/r d4T+3TC+LPV/r Hospital Likas Malaysia <3yr:AZT+3TC or ddI+NVP≥3yr:AZT+3TC or ddI+EFV 2 new NRTI+LPV/r d4T+ddI+LPV/r Hospital Penang Malaysia <3yr:AZT+3TC or ddI+NVP≥3yr:AZT+3TC or ddI+EFV 2 new NRTI+LPV/r -- Hospital Raja Perempuan Zainab Malaysia <3yr:AZT+3TC or ddI+NVP≥3yr:AZT+3TC or ddI+EFV 2 new NRTI+LPV/r d4T+ddI+LPV/r Chiang Mai University Medical Centre Thailand d4T or AZT+3TC+NVP or EFV ddI+ABC or 3TC+PI/r AZT+3TC+LPV/r Chiang Rai Regional Hospital Thailand d4T or AZT+3TC+NVP or EFV ddI+ABC or 3TC+PI/r AZT+3TC+LPV/r HIV-NAT Thailand d4T or AZT+3TC+NVP or EFV ddI+ABC or 3TC+PI/r AZT+3TC+LPV/r Khon Kaen University Medical Centre Thailand d4T or AZT+3TC+NVP or EFV ddI+ABC or 3TC+PI/r AZT+ddI+LPV/r Siriraj Hospital Thailand d4T or AZT+3TC+NVP or EFV ddI+ABC or 3TC+PI/r AZT+ddI+LPV/r Children's Hospital 1 Vietnam d4T+3TC+NVP ABC+ddI+LPV/r -- Children's Hospital 2 Vietnam d4T+3TC+NVP ABC+ddI+LPV/r ABC+ddI+LPV/r National Hospital of Paediatrics Vietnam d4T+3TC+NVP ABC+ddI+LPV/r ABC+ddI+LPV/r IeDEA Southern Africa Lighthouse Clinic Malawi d4T+3TC+NVP ABC+ddI+LPV/r AZT+3TC+LPV/r Paediatric Day Hospital, Maputo Mozambique d4T or AZT+3TC+NVP or EFVIf NNRTI exposure:d4T or AZT+3TC+LPV/r ABC+ddI+LPV/r None Rahima Moosa Mother and Child Hospital South Africa <3yr/10kg:d4T+3TC+LPV/r>3yr/10kg:d4T+3TC+EFV AZT+ddI+LPV/r ABC+3TC+LPV/r Gugulethu Community Health Centre South Africa <3yr/10kg:d4T+3TC+LPV/r>3yr/10kg:d4T+3TC+EFV AZT+ddI+LPV/r AZT+ddI+EFV or LPV/r ABC+3TC+LPV/r Harriet Shezi Clinic South Africa <3yr/10kg:d4T+3TC+LPV/r>3yr/10kg:d4T+3TC+EFV AZT+ddI+LPV/r AZT+ddI+LPV/r Khayelitsha Community Health Centre South Africa <3yr/10kg:d4T+3TC+LPV/r>3yr/10kg:d4T+3TC+EFV AZT+ddI+LPV/r AZT+ddI+LPV/r McCord Hospital South Africa <3yr/10kg:d4T+3TC+LPV/r>3yr/10kg:d4T+3TC+EFV AZT+ddI+LPV/r AZT+ddI+LPV/r Red Cross Children's Hospital South Africa <3yr/10kg:d4T+3TC+LPV/r>3yr/10kg:d4T+3TC+EFV AZT+ddI+LPV/r AZT+ddI+EFV Tygerberg Hospital South Africa <3yr/10kg:d4T+3TC+LPV/r>3yr/10kg:d4T+3TC+EFV AZT+ddI+LPV/r AZT+ddI+LPV/r Newlands Clinic Zimbabwe AZT+3TC+NVP ddI+3TC+LPV/r d4T+3TC+NVP *Content reflects current recommendations at the time of the survey. WHO first-line regimen recommendations at the time of the survey included two NRTIs with one NNRTI or two NRTIs with one PI/r if the infant had previous NNRTI exposure [10,17]; second-line regimen recommendations after NNRTI failure included two NRTIs with one PI/r or unboosted nelfinavir in limited circumstances. d4T - stavudine; AZT - zidovudine; 3TC - lamivudine; NVP - nevirapine; EFV - efavirenz; ABC - abacavir; ddI - didanosine; LPV/r - ritonavir-boosted lopinavir; TDF - tenofovir; FTC - emtricitabine; NRTI - nucleoside reverse transcriptase inhibitor; NNRTI - non-nucleoside reverse transcriptase inhibitor.